Mefvir Tablet is a combination pharmaceutical formulation containing Drotaverine 80 mg and Mefenamic Acid 250 mg, designed for the management of pain associated with smooth muscle spasms and inflammatory conditions. Drotaverine, an antispasmodic agent, acts by inhibiting phosphodiesterase-IV, leading to increased intracellular cyclic AMP levels and subsequent relaxation of smooth muscles, thereby alleviating spasmodic pain. Mefenamic Acid, a nonsteroidal anti-inflammatory drug (NSAID), exerts analgesic, anti-inflammatory, and antipyretic effects by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), reducing the synthesis of prostaglandins responsible for pain and inflammation. The synergistic action of these two active ingredients makes Mefvir Tablet effective in treating conditions such as dysmenorrhea, renal colic, biliary colic, and musculoskeletal pain accompanied by spasms. It is indicated for short-term use to provide symptomatic relief. Caution is advised in patients with a history of hypersensitivity to NSAIDs, peptic ulcers, hepatic or renal impairment, and cardiovascular disorders. Mefvir Tablet should be administered under medical supervision, with dosage adjustments based on clinical response and patient tolerance. Common adverse effects may include gastrointestinal discomfort, nausea, dizziness, and allergic reactions. Patients are advised to report any unusual symptoms promptly to their healthcare provider.